Evidence map›Paper›PMID 42236689›Full record

ArticleNature communications2026

Non-coding structural variants disrupt FOXG1 transcriptional regulation in early neurodevelopment.

Lisa Hamerlinck, Eva D'haene, Michael B Vaughan, Nore Van Loon, María Del Rocío Pérez Baca, Sebastian Leimbacher, Michael Kosicki, Lara Colombo, Lukas Genbrugge, Lies Vantomme and 11 more

Abstract read
In one paragraph

Article in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

Lisa Hamerlinck *Center for Medical Genetics Ghent, Ghent University Hospital, Ghent, Belgium.ORCID http://orcid.org/0000-0002-8210-2355
Eva D'haene *Center for Medical Genetics Ghent, Ghent University Hospital, Ghent, Belgium.ORCID http://orcid.org/0000-0002-5936-8294
Michael B VaughanCenter for Medical Genetics Ghent, Ghent University Hospital, Ghent, Belgium.ORCID http://orcid.org/0000-0002-9979-1265
Nore Van LoonCenter for Medical Genetics Ghent, Ghent University Hospital, Ghent, Belgium.
María Del Rocío Pérez BacaCenter for Medical Genetics Ghent, Ghent University Hospital, Ghent, Belgium.ORCID http://orcid.org/0000-0002-0117-9255
Sebastian LeimbacherCenter for Medical Genetics Ghent, Ghent University Hospital, Ghent, Belgium.
Michael KosickiEnvironmental Genomics & System Biology Division, Lawrence Berkeley National Laboratory, Berkeley, CA, USA.ORCID http://orcid.org/0000-0001-7173-8852
Lara ColomboCenter for Medical Genetics Ghent, Ghent University Hospital, Ghent, Belgium.
Lukas GenbruggeCenter for Medical Genetics Ghent, Ghent University Hospital, Ghent, Belgium.
Lies VantommeCenter for Medical Genetics Ghent, Ghent University Hospital, Ghent, Belgium.
Esperanza DaalCenter for Medical Genetics Ghent, Ghent University Hospital, Ghent, Belgium.
Luiza Lorena Pires RamosMolecular Neurogenomics Group, VIB Center for Molecular Neurology, VIB, Antwerp, Belgium.ORCID http://orcid.org/0000-0003-1668-1683
Daniela Mircheva Avdjieva-TzavellaDepartment of Clinical Genetics, University Pediatric Hospital, Medical University-Sofia, Sofia, Bulgaria.
Himanshu GoelHunter Genetics, Newcastle, NSW, Australia.ORCID http://orcid.org/0000-0001-6448-6618
Koen DevriendtCenter for Human Genetics, University Hospitals Leuven, Leuven, Belgium.ORCID http://orcid.org/0000-0002-3651-2548
Albena JordanovaMolecular Neurogenomics Group, VIB Center for Molecular Neurology, VIB, Antwerp, Belgium.
Annelies DheedeneCenter for Medical Genetics Ghent, Ghent University Hospital, Ghent, Belgium.
Axel ViselEnvironmental Genomics & System Biology Division, Lawrence Berkeley National Laboratory, Berkeley, CA, USA.ORCID http://orcid.org/0000-0002-4130-7784
Björn MentenCenter for Medical Genetics Ghent, Ghent University Hospital, Ghent, Belgium.ORCID http://orcid.org/0000-0001-8182-659X
Bert CallewaertCenter for Medical Genetics Ghent, Ghent University Hospital, Ghent, Belgium.ORCID http://orcid.org/0000-0002-9743-4205
Sarah VergultCenter for Medical Genetics Ghent, Ghent University Hospital, Ghent, Belgium. Sarah.Vergult@UGent.be.ORCID http://orcid.org/0000-0002-0816-6262

Funding

Generation of an In Vivo Human Genome Transcriptional Enhancer DatasetR01HG003988 · NHGRI · UNIVERSITY OF CALIF-LAWRENC BERKELEY LAB · PI Len Alexander Pennacchio · 2006 to 2026
$24.1M
Bijzonder Onderzoeksfonds (Special Research Fund) BOF.BAF.2024.0263.01Bijzonder Onderzoeksfonds (Special Research Fund) BOF.BAF.2025.0095.01Bijzonder Onderzoeksfonds (Special Research Fund) BOF.STG.2019.0103.01Fonds Wetenschappelijk Onderzoek (Research Foundation Flanders) 1520518NFonds Wetenschappelijk Onderzoek (Research Foundation Flanders) G055422NFonds Wetenschappelijk Onderzoek (Research Foundation Flanders) G063423NNHGRI NIH HHS R01 HG003988Wellcome Trust
6 · The paper itself

Abstract

The FOXG1 transcription factor is a crucial regulator of embryonic brain development. Pathogenic FOXG1 variants cause FOXG1 syndrome. Although structural variants in the non-coding region downstream of FOXG1 have been reported in 38 individuals with similar characteristics, the regulatory pathomechanisms remain unknown. Here, we identify two non-coding structural variants in individuals with FOXG1 syndrome-like features, allowing us to delineate a ~ 124 kb commonly affected regulatory region. Using epigenomic profiling and in vivo enhancer assays, we characterize and validate regulatory elements within the commonly affected regulatory region and wider FOXG1 TAD. We see strong activation of previously validated forebrain enhancers, and identify an enhancer cluster and progenitor-specific enhancer region that are strongly activated during forebrain-directed neural progenitor cell differentiation, a process in which FOXG1 is an important regulator. Perturbation of these elements results in varying degrees of reduced FOXG1 transcription in forebrain neural progenitor cells and in population shifts within these cells, while removal of the TAD boundary leads to aberrant expression of the neighbouring PRKD1 gene. Our findings characterize enhancer and architectural elements essential for proper FOXG1 transcription during neurodevelopment, therefore improving variant interpretation in this region.

Indexed as

Forkhead Transcription FactorsGene Expression Regulation, DevelopmentalNerve Tissue ProteinsAnimalsCell DifferentiationEnhancer Elements, GeneticHumansNeural Stem CellsNeurodevelopmentProsencephalonTranscription, GeneticForkhead Transcription FactorsFOXG1 protein, humanNerve Tissue Proteins

Identifiers

PMID42236689
PMCPMC13396769

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.